Potential First-in-Class Therapy Gets Fast-Tracked for PTSD

Brian Park, PharmD https://www.empr.com/home/news/drugs-in-the-pipeline/potential-first-in-class-therapy-gets-fast-tracked-for-ptsd/ The Food and Drug Administration (FDA) has granted Fast Track designation to BNC210 (Bionomics Limited) for the treatment of post-traumatic stress disorder (PTSD) and other trauma-related and stressor-related disorders. BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor being developed for the treatment of PTSD, anxiety…